Laboratorios Farmaceuticos Rovi（ROVI）株式概要
Laboratorios Farmaceuticos Rovi, S.A.は、スペイン、欧州連合、OECD諸国、および国際的に医薬品の製造、販売、マーケティングを行っている。 詳細
ROVI Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€51.25
FV
14.3% 割高 内在価値ディスカウント4.00%
Revenue growth p.a.
141
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Laboratorios Farmaceuticos Rovi, S.A. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €58.60 |
| 52週高値 | €86.70 |
| 52週安値 | €51.65 |
| ベータ | 0.22 |
| 1ヶ月の変化 | -1.18% |
| 3ヶ月変化 | -26.57% |
| 1年変化 | 6.74% |
| 3年間の変化 | 38.40% |
| 5年間の変化 | -0.51% |
| IPOからの変化 | 486.00% |
最新ニュース
ナラティブの更新 • Jun 18
ROVI: Contract Manufacturing Expansion And Dividend Capacity Will Support Future Share Returns
Analysts have trimmed their fair value estimate for Laboratorios Farmaceuticos Rovi stock from about €76.49 to roughly €75.38, citing a slightly less optimistic outlook on revenue growth, profit margins and future P/E multiples after recent downgrades from several firms. Analyst Commentary Recent commentary around Laboratorios Farmaceuticos Rovi focuses on how recent downgrades affect expectations for execution, valuation and growth, rather than on any single data point in isolation.ナラティブの更新 • Jun 02
ROVI: Medium Term Contract Risks Will Still Support Future Returns
Analysts have trimmed the fair value estimate for Laboratorios Farmaceuticos Rovi from about €82.48 to €76.49 after recent downgrades flagged softer revenue growth assumptions, slightly lower profit margins and a modestly higher future P/E, with some noting medium term risks linked to Moderna exposure and declining vaccination volumes. Analyst Commentary Recent research has tilted more cautious on Laboratorios Farmaceuticos Rovi, with several downgrades pointing to a reassessment of growth, margins and risk tied to its partner exposure.Recent updates
ナラティブの更新 • Jun 18
ROVI: Contract Manufacturing Expansion And Dividend Capacity Will Support Future Share Returns
Analysts have trimmed their fair value estimate for Laboratorios Farmaceuticos Rovi stock from about €76.49 to roughly €75.38, citing a slightly less optimistic outlook on revenue growth, profit margins and future P/E multiples after recent downgrades from several firms. Analyst Commentary Recent commentary around Laboratorios Farmaceuticos Rovi focuses on how recent downgrades affect expectations for execution, valuation and growth, rather than on any single data point in isolation.ナラティブの更新 • Jun 02
ROVI: Medium Term Contract Risks Will Still Support Future Returns
Analysts have trimmed the fair value estimate for Laboratorios Farmaceuticos Rovi from about €82.48 to €76.49 after recent downgrades flagged softer revenue growth assumptions, slightly lower profit margins and a modestly higher future P/E, with some noting medium term risks linked to Moderna exposure and declining vaccination volumes. Analyst Commentary Recent research has tilted more cautious on Laboratorios Farmaceuticos Rovi, with several downgrades pointing to a reassessment of growth, margins and risk tied to its partner exposure.分析記事 • Feb 09
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブの更新 • Feb 03
ROVI: Slightly Higher Fair Value And P/E Will Support Future Returns
Analysts have nudged their price target for Laboratorios Farmaceuticos Rovi slightly higher, with a modest upward revision in fair value tied to refreshed assumptions for revenue, profit margins and future P/E multiples. Valuation Changes Fair Value: Adjusted slightly higher from €81.97 to €82.48 per share, reflecting refreshed model assumptions.ナラティブの更新 • Jan 20
ROVI: Stable Returns And Slightly Higher Multiple Will Support Future Earnings
Analysts have nudged up their fair value estimate for Laboratorios Farmaceuticos Rovi from €80.96 to €81.97, citing slightly higher revenue growth assumptions, a small adjustment in expected profit margins, and a modestly higher future P/E multiple as key drivers of the new target. Valuation Changes Fair Value Estimate was adjusted slightly from €80.96 to €81.97, reflecting a small uplift in the modelled valuation.ナラティブの更新 • Jan 05
ROVI: Stable Returns And Margins Will Support Stronger Future Earnings
Analysts have kept their price target for Laboratorios Farmaceuticos Rovi unchanged, citing stable assumptions around a fair value of €80.96, a discount rate of 7.65%, revenue growth of 12.59%, a profit margin of 23.81% and a future P/E of 20.93 to support their view. Valuation Changes Fair Value: The fair value estimate remains unchanged at €80.96 per share, reflecting the same core valuation outcome as before.ナラティブの更新 • Dec 15
ROVI: Stable Margins And Growth Outlook Will Support Stronger Future Earnings
Analysts have modestly adjusted their price targets for Laboratorios Farmaceuticos Rovi, now valuing the shares around €80.96. They reiterate expectations for solid double digit revenue growth, resilient profit margins, and a stable long term valuation multiple.ナラティブの更新 • Dec 01
ROVI: Increasing Profit Margins Will Drive Stronger Earnings Outlook
Analysts have modestly increased their price target for Laboratorios Farmaceuticos Rovi to €80.96 per share. They cite improving profit margin forecasts as the primary driver of the change.ナラティブの更新 • Nov 17
ROVI: Revenue Acceleration Projected To Drive Upside Despite Margin Pressure
Analysts have raised their price target for Laboratorios Farmaceuticos Rovi from €79.41 to €80.96. They cite improved revenue growth projections, despite slightly lower profit margins and a marginal increase in the discount rate.分析記事 • Nov 09
Here's What Analysts Are Forecasting For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) After Its Third-Quarter Results
It's been a mediocre week for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shareholders, with the stock dropping...分析記事 • Nov 06
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jun 14
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...分析記事 • May 27
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...分析記事 • Feb 09
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
新しいナラティブ • Dec 26
Okedi Expansion And Heparin Integration To Boost Revenue And Net Margins
Focus on Okedi and enoxaparin indicates potential revenue growth and improved profit margins from European development and heparin sales volume.分析記事 • Nov 10
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
There's been a notable change in appetite for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shares in the week...分析記事 • Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 18x, you may consider...分析記事 • Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €146...分析記事 • Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Key Insights Laboratorios Farmaceuticos Rovi will host its Annual General Meeting on 24th of June Salary of €743.0k is...分析記事 • May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 16x, you may consider...分析記事 • Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €92.64...分析記事 • Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Key Insights The projected fair value for Laboratorios Farmaceuticos Rovi is €73.44 based on 2 Stage Free Cash Flow to...分析記事 • Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €52.88 based on 2 Stage Free Cash Flow to Equity...分析記事 • May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €51.68 based on 2 Stage Free Cash Flow to Equity...分析記事 • Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
In this article we are going to estimate the intrinsic value of Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) by...分析記事 • Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Laboratorios...分析記事 • Jun 15
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...株主還元
| ROVI | ES Pharmaceuticals | ES 市場 | |
|---|---|---|---|
| 7D | 1.0% | 1.2% | 0.2% |
| 1Y | 6.7% | 5.2% | 33.7% |
業界別リターン: ROVI過去 1 年間で5.2 % の収益を上げたSpanish Pharmaceuticals業界を上回りました。
リターン対市場: ROVIは、過去 1 年間で33.7 % のリターンを上げたSpanish市場を下回りました。
価格変動
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 3.1% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in ES Market | 6.5% |
| 10% least volatile stocks in ES Market | 0.7% |
安定した株価: ROVIの株価は、 Spanish市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: ROVIの weekly volatility ( 6% ) は過去 1 年間安定していますが、依然としてSpanishの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1946 | 1,998 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A.は、スペイン、欧州連合、OECD加盟国、および国際的に医薬品の製造、販売、マーケティングを行っている。同社は、Ameride、Bertanel、Bluxam、Enoxaparin Rovi、Calcium Vitamine D3 Rovi、Exxiv、Prinvil、Rhodogil、Glufan、Hibor、Hirobriz Breezhaler、Neparvis、Medicebran、Medikinet、Mysimba、Orvatez、Tryptizol、Ulunar Breezhaler、Volutsaなどの医療用医薬品を提供している。また、イオメロン、イオパミロ、マルチハンス、Yプロハンス、ソノビュー、エンパワクタプラス、エンパワーマー、CTエクスプレスなどの病院向け製品、フィブリリンブランドでのカテーテルケア、ヘパリンナトリウム・ロビなども提供している。また、プレフィルドシリンジ、バイアル、カートリッジなどの注射剤、固形製剤の製造・包装サービスも提供している。同社の製品は、心臓病学、骨関節／女性健康、麻酔／疼痛、画像診断用造影剤、中枢神経系、泌尿器、内分泌、呼吸器、プライマリーヘルスケア分野で使用されている。1946年に設立され、スペインのマドリードに本社を置く。Laboratorios Farmaceúticos Rovi, S.A.はNorbel Inversiones, S.L.の子会社である。
Laboratorios Farmaceuticos Rovi, S.A. 基礎のまとめ
| ROVI 基礎統計学 | |
|---|---|
| 時価総額 | €3.00b |
| 収益（TTM） | €131.82m |
| 売上高(TTM) | €741.09m |
22.7x
PER（株価収益率4.0x
P/SレシオROVI は割高か？
公正価値と評価分析を参照収益と収入
| ROVI 損益計算書（TTM） | |
|---|---|
| 収益 | €741.09m |
| 売上原価 | €267.01m |
| 売上総利益 | €474.08m |
| その他の費用 | €342.26m |
| 収益 | €131.82m |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 23, 2026
| 一株当たり利益（EPS） | 2.58 |
| グロス・マージン | 63.97% |
| 純利益率 | 17.79% |
| 有利子負債／自己資本比率 | 14.6% |
ROVI の長期的なパフォーマンスは？
過去の実績と比較を見る| Laboratorios Farmaceuticos Rovi 配当日 | |
|---|---|
| 配当落ち日 | Jul 13 2026 |
| 配当支払日 | Jul 15 2026 |
| 配当落ちまでの日数 | 14 days |
| 配当支払日までの日数 | 16 days |
ROVI 配当は確実ですか？
ROVI 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/28 18:55 |
| 終値 | 2026/06/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Laboratorios Farmaceuticos Rovi, S.A. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |